Impact of Uncontrolled Motor Fluctuations in Parkinson’s Disease: Real-World Insights from the PROSPECT Observational Study

{"INTRODUCTION:":[0],"Limited":[1],"real-world":[2,27],"data":[3],"exist":[4],"around":[5],"the":[6,97],"long-term":[7],"impact":[8],"of":[9,33,88,111,120,230],"uncontrolled":[10,61],"motor":[11,38,62,106,308],"fluctuations":[12,39,63],"in":[13,105,179,195,273],"Parkinson's":[14],"disease":[15],"(PD).":[16],"With":[17],"this":[18],"first-ever,":[19],"prospective,":[20],"observational":[21,51],"study,":[22],"we":[23],"sought":[24],"to":[25,167,241],"describe":[26],"treatment":[28],"patterns":[29],"and":[30,37,60,92,107,118,147,174,203,270,275],"longitudinal":[31],"outcomes":[32],"patients":[34,155,293],"with":[35,57,192,283,294,306],"PD":[36,59,72,144,164,295],"inadequately":[40],"controlled":[41],"by":[42,96],"oral":[43,71,143,163,284,299,315],"medications.":[44,300],"METHODS:":[45],"PROSPECT":[46],"was":[47,304],"a":[48,176,257],"24-month":[49],"multicountry":[50],"study":[52],"that":[53],"included":[54,100],"229":[55],"adults":[56],"idiopathic":[58],"(≥":[64],"2.5":[65],"h/day":[66],"\\"off\\"":[67,180,259],"time)":[68],"on":[69,142,162,298,314],"optimized":[70],"medications":[73,145,165,285,316],"who":[74,140,149,248,312],"were":[75,84,93,126,136,226],"device-aided":[76,82,151,228,250,289],"therapy-naive.":[77],"Treatment":[78],"modifications,":[79],"including":[80],"adding":[81],"therapy,":[83,229],"made":[85],"as":[86,245],"part":[87],"routine":[89],"clinical":[90],"care":[91],"not":[94,169],"assigned":[95],"study.":[98],"Assessments":[99],"change":[101,272],"from":[102],"baseline":[103,129],"(CFB)":[104],"non-motor":[108],"symptoms,":[109,309],"activities":[110],"daily":[112],"living":[113],"(ADL;":[114],"MDS-UPDRS":[115],"Part":[116],"II),":[117],"quality":[119],"life":[121],"(QoL;":[122],"EQ-5D-5L,":[123],"PDQ-39).":[124],"Outcomes":[125],"adjusted":[127],"for":[128],"differences":[130],"using":[131],"linear":[132],"regression.":[133],"Subgroup":[134],"analyses":[135],"performed":[137],"among":[138],"those":[139,148,311],"remained":[141,160,296,313],"only":[146],"initiated":[150,249],"therapy.":[152],"RESULTS:":[153],"Most":[154],"(80.3%,":[156],"n":[157,223,253],"=":[158,187,198,201,207,210,214,218,224,234,254,263],"184)":[159],"solely":[161],"due":[166],"clinician":[168],"offering":[170],"or":[171,243],"patient":[172],"refusal,":[173],"showed":[175,256,317],"small":[177],"reduction":[178,261],"time":[181,240,260],"(CFB":[182,197,262],"-":[183,215,264],"0.7":[184],"h/day,":[185,266],"p":[186,200,209,217,267],".006)":[188],"at":[189,277],"24":[190,278],"months,":[191,279],"nominal":[193],"decline":[194],"ADL":[196,274],"1.5,":[199],".010)":[202],"QoL":[204,276],"(PDQ-39":[205],"CFB":[206,213],"2.6,":[208],".010;":[211],"EQ-5D-5L":[212],"0.04,":[216],".017).":[219],"Approximately":[220],"half":[221],"(49.8%,":[222],"114)":[225],"offered":[227],"whom":[231],"44.7%":[232],"(n":[233],"51/114)":[235],"declined,":[236],"mainly":[237],"citing":[238],"needing":[239],"decide":[242],"perception":[244],"unnecessary.":[246],"Patients":[247],"therapy":[251,290,302],"(19.7%,":[252],"45)":[255],"meaningful":[258,319],"2.2":[265],"<":[268],".0001)":[269],"no":[271,318],"versus":[280],"slight":[281],"worsening":[282],"only.":[286],"CONCLUSION:":[287],"Despite":[288],"eligibility,":[291],"most":[292],"exclusively":[297],"Device-aided":[301],"initiation":[303],"associated":[305],"improved":[307],"while":[310],"change.":[320]}